EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30 –40% of patients still show limited response. ...

https://clintransmed.springeropen.com/articles/10.1186/s40169-020-0269-y

Source: Clinical and Translational Medicine - February 17, 2020 Category: Internal Medicine Authors: Qiufan Zheng, Shaodong Hong, Yan Huang, Hongyun Zhao, Yunpeng Yang, Xue Hou, Yuanyuan Zhao, Yuxiang Ma, Ting Zhou, Yaxiong Zhang, Wenfeng Fang and Li Zhang Tags: Research Source Type: research

More News: Cancer | Cancer & Oncology | Internal Medicine | Lung Cancer | Non-Small Cell Lung Cancer